A secretive, Google-backed lab is using artificial intelligence to invent new medicines for humanity's worst illnesses. But ...

Google DeepMind's moonshot, Isomorphic Labs, is gearing up to launch its first ever human trial of AI-designed drugs. The ...

Isomorphic Labs, backed by Google's parent company Alphabet, is preparing for its first human clinical trials for cancer drugs designed entirely by artificial intelligence.

Alphabet’s Isomorphic Labs is preparing to begin human trials of a drug designed using AI, based on protein modelling ...

Google DeepMind's Isomorphic Labs is preparing for human trials of AI-designed drugs, marking a significant advancement in pharmaceutical innovation. President Colin Murdoch revealed the company's ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is pairing ...

Alphabet’s Isomorphic Labs is preparing to launch human trials of AI-designed drugs, its president, Colin Murdoch, told Fortune. Born from DeepMind’s AlphaFold breakthrough, the company is ...

Google DeepMind CEO Demis Hassabis has said that AI can have a serious crack at solving all diseases in the coming years. And ...

Google parent Alphabet has drawn on its DeepMind artificial intelligence division to form a drug discovery unit that it calls Isomorphic Labs. The UK-registered company will be able to tap into ...

Isomorphic Labs has raised a whopping $600 million to refine its artificial intelligence-powered drug discovery engine, advance its pipeline, and expand its headcount in its first external funding ...

The startup has opened labs in New York and Taipei, but it’s competing in AI drug development with larger biotech firms and newcomers such as Isomorphic Labs, the spinoff from Google DeepMind.